

Special Issue

Immune Checkpoint Inhibitors for Genitourinary Cancers

Message from the Guest Editor

The treatment of genitourinary malignancies has significantly evolved recently due to advances in our understanding of immune checkpoints. Renal cell carcinoma, urothelial carcinoma, and prostate adenocarcinoma are the most commonly encountered genitourinary malignancies. Immune checkpoint inhibitors have revolutionized cancer therapy, which result in durable clinical benefit. Several agents are currently used in clinic, and many of them is currently under development. This Special Issue is focused on recent immune checkpoints approaches, and novel immune therapeutics, treatment algorithm, and management of immune related toxicities in genitourinary malignancies.

Guest Editor

Dr. Mehmet Asim Bilen

Department of Hematology and Medical Oncology, Emory University
School of Medicine, Atlanta, GA, USA.

Deadline for manuscript submissions

closed (31 May 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/58850

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)